PM
OVID icon

Prosight Management’s Ovid Therapeutics OVID Stock Holding History

Prosight Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-729,208
Closed -$860K – 46
2024
Q3 		$860K Sell
729,208
-345,792
-32% -$361K 0.21% 41
2024
Q2 		$827K Buy
1,075,000
+91,800
+9% +$255K 0.25% 41
2024
Q1 		$3M Buy
+983,200
New +$3.29M 0.83% 32

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prosight Management's OVID Position: Q4 2024 in Review

Prosight Management sold out of Ovid Therapeutics (OVID) in Q4 2024, closing a stake of 729,208 shares — an estimated $860K sold.

Prosight Management first reported a position in OVID in Q1 2024 and held it in 3 quarters. The position peaked at $3M in Q1 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q4 2024.

  • Prosight Management reported no remaining Ovid Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prosight Management sold 729,208 Ovid Therapeutics shares in Q4 2024, an estimated $860K.
  • Prosight Management first reported a position in Ovid Therapeutics in Q1 2024 and held it in 3 quarters.
  • Prosight Management's Ovid Therapeutics position peaked at $3M in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2024.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.